NuGen Medical Devices Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Ian Heynen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.5yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Ian Heynen

less than a year

Amtszeit

Mr. Ian Heynen serves as CEO at NuGen Medical Devices Inc. since November 01, 2023. He serves as the Chief Financial Officer of Sentinelle Medical, Inc. Mr. Heynen has strong operating and financial leader...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anthony Di Benedetto	Executive Chairman	1.3yrs	keine Daten	1.05% CA$ 226.5k
Richard Buzbuzian	President & Director	1.3yrs	keine Daten	3.13% CA$ 676.7k
Veronique Laberge	CFO & Secretary	1.3yrs	CA$90.00k	0.35% CA$ 75.0k
Nicky Canton	Executive VP & COO	no data	CA$185.68k	0.046% CA$ 10.0k
Karen Dunlap	Interim Chief Customer Officer & Director	1.5yrs	CA$11.15k	0.069% CA$ 15.0k
Ian Heynen	Chief Executive Officer	less than a year	keine Daten	keine Daten
Elisha Dillon	Head of Global Sales & Strategic Partnerships	2.6yrs	keine Daten	keine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: NGMDDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anthony Di Benedetto	Executive Chairman	1.3yrs	keine Daten	1.05% CA$ 226.5k
Richard Buzbuzian	President & Director	1.3yrs	keine Daten	3.13% CA$ 676.7k
Karen Dunlap	Interim Chief Customer Officer & Director	2.7yrs	CA$11.15k	0.069% CA$ 15.0k
Christopher Irwin	Independent Director	less than a year	keine Daten	0.21% CA$ 46.0k
Erik Emerson	Member of Advisory Board	1.7yrs	keine Daten	keine Daten
John Leombruno	Independent Director	2.7yrs	keine Daten	2.44% CA$ 528.6k
Greg Gironda	Member of Advisory Board	1.8yrs	keine Daten	keine Daten
Philip Cortese	Independent Director	1.4yrs	keine Daten	keine Daten

1.5yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: NGMDDie Vorstandsmitglieder gelten nicht als erfahren ( 1.5 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

NuGen Medical Devices Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

CEO, President & Director exercised options to buy CA$594k worth of stock.

Nugen Medical Devices Inc. Announces Executive Changes

Less than half of directors are independent

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

NuGen Medical Devices Inc. Appoints Greg Gironda to Its Advisory Board

Recent updates

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.017 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.056 loss per share (vs CA$0.062 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in 3Q 2022)

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

NuGen Medical Devices Inc. Presents New Data from Preliminary Trial That Semaglutide (Ozempic ) Is Chemically Stable After It Is Administered Through Nugen 's InsuJet Needle-Free Injection Device

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.016 loss in 2Q 2022)

New minor risk - Insider selling

CEO, President & Director exercised options to buy CA$594k worth of stock.

First quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 1Q 2022)

NuGen Medical Devices Inc. announced that it has received CAD 0.45 million in funding

Full year 2022 earnings released: CA$0.062 loss per share (vs CA$0.10 loss in FY 2021)

NuGen Medical Devices Inc. announced that it has received CAD 2.5 million in funding

NuGen Medical Devices Inc. announced that it has received CAD 0.125 million in funding

Nugen Medical Devices Inc. Announces Executive Changes

NuGen Medical Devices Inc. announced that it expects to receive CAD 3 million in funding

Less than half of directors are independent

Third quarter 2022 earnings released

NuGen Medical Devices Inc. Announces the Launch of Its InsuJet Needle-Free Injection Device in Canada

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

NuGen Medical Devices Inc. Appoints Greg Gironda to Its Advisory Board

NuGen Medical Devices Inc. announced that it has received CAD 0.640376 million in funding

Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.021 loss in 2Q 2021)

NuGen Medical Devices Inc. announced that it expects to receive CAD 0.4118 million in funding

Nugen M.D. Receives Additional Health Canada Approval for Insulin Specific Needle-Free Injection System

NuGen Medical Devices Inc. Launches PetJet Providing Needle-Free Injections for Domesticated Pets

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.013 loss in 1Q 2021)

NuGen Medical Devices Inc., Annual General Meeting, Jun 17, 2022

Independent Director recently bought CA$53k worth of stock

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Independent Director recently bought CA$304k worth of stock

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter